Ernexa Therapeutics Inc (NASDAQ:ERNA) stock surged 65.8% after announcing a manufacturing collaboration with Cellipont Bioservices to advance its lead cancer cell therapy toward clinical trials.
The partnership will focus on Engineering, Differentiation, and Production activities for ERNA-101, Ernexa’s cell therapy being developed for ovarian cancer treatment. Cellipont will support the current Good Manufacturing Practice development and scale-up of the manufacturing process as the therapy heads toward clinical trials.
ERNA-101 is based on Ernexa’s technology that engineers induced pluripotent stem cells into induced mesenchymal stem cells (iMSCs), which have a unique ability to migrate toward tumors. The therapy is designed as an allogeneic, off-the-shelf treatment that doesn’t require patient-specific cell harvesting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.